Table 3.

Associations between perceptions related to HPV screening (in general) and HPV vaccination with the uptake of HPV screening (among participants who completed Month 12 follow-up, n = 274).

	OR (95%CI)	P-values	AOR (95%CI)	P-values
Perceived susceptibility scale	1.21 (1.05, 1.39)	0.009	1.16 (1.00, 1.34)	0.046
Perceived severity scale	1.09 (0.97, 1.23)	0.16	1.08 (0.95, 1.23)	0.23
Perceived benefit scale	0.97 (0.78, 1.21)	0.79	1.00 (0.79, 1.28)	0.99
Perceived barrier scale	0.88 (0.70, 1.12)	0.30	0.90 (0.70, 1.15)	0.39
Cue to action	1.39 (0.97, 1.97)	0.07	1.29 (0.90, 1.85)	0.17
Perceived self-efficacy	0.95 (0.66, 1.36)	0.78	0.90 (0.62, 1.32)	0.61
Behavioral intention to take up HPV screening
Perceived chance to take up clinician-collected HPV screening in the next year if it cost HK $700 (US $89.7) per episode
Very low/low/moderate	1.0		1.0
High/very high	1.80 (0.80, 4.03)	0.16	1.67 (0.71, 3.97)	0.24
Perceived chance to take up clinician-collected HPV screening in the next year if it is provided for free
Very low/low/moderate	1.0		1.0
High/very high	1.66 (0.61, 4.49)	0.32	1.21 (0.43, 3.42)	0.72
Uptake of HPV vaccination during the study period
No	1.00
Yes	7.77 (3.54, 17.03)	<0.001	7.03 (3.07, 16.13)	<0.001

AOR, Adjusted Odds Ratio, odds ratios adjusted for significant baseline background characteristics (i.e., self-reported HIV sero-status, and HPV screening in the past year).

CI, Confidence Interval; HPV, Human Papillomavirus; OR, Crude Odds Ratios.